Inclusion Criteria:  Documented physician-diagnosed asthma for at least 12 months prior to Visit 1. Morning pre-bronchodilator FEV1 (Forced expiratory volume) of > 50% predicted normal value at Visit 1 or Visit 2. Body weight ≥ 40 kg. For women of childbearing potential, a negative urine pregnancy test is required prior to administration of study intervention at Visit 3. Must have 'not well-controlled' asthma.  Exclusion Criteria:  Clinically important pulmonary disease other than asthma. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment. Life-threatening asthma History of cancer. Allergy to eggs, if egg based influenza vaccine will be administered. History of anaphylaxis to any biologic therapy. Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible. History of alcohol or drug abuse within 12 months prior to the date of informed consent. Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures during the conduct of the study.